Parallax Volatility Advisers
CLSD

Parallax Volatility Advisers’s Clearside Biomedical CLSD Stock Holding History

Parallax Volatility Advisers’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-684
Closed -$110K – 2640
2018
Q2 		$110K Sell
684
-33
-5% -$5.56K ﹤0.01% 1469
2018
Q1 		$115K Buy
717
+510
+246% +$62.1K ﹤0.01% 1348
2017
Q4 		$22K Buy
+207
New +$22.2K ﹤0.01% 3636

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Parallax Volatility Advisers's CLSD Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Clearside Biomedical (CLSD) in Q3 2018, closing a stake of 684 shares — an estimated $110K sold.

Parallax Volatility Advisers first reported a position in CLSD in Q4 2017 and held it in 3 quarters. The position peaked at $115K in Q1 2018. 89 funds tracked by Wall St. Rank hold CLSD as of Q3 2018.

  • Parallax Volatility Advisers reported no remaining Clearside Biomedical position as of Q3 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 684 Clearside Biomedical shares in Q3 2018, an estimated $110K.
  • Parallax Volatility Advisers first reported a position in Clearside Biomedical in Q4 2017 and held it in 3 quarters.
  • Parallax Volatility Advisers's Clearside Biomedical position peaked at $115K in Q1 2018.
  • 89 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.